Corporate | 23 November 2011 10:10

STADA sales companies very successful in large-volume 7th AOK tender in the German generics market

STADA Arzneimittel AG / Key word(s): Miscellaneous

23.11.2011 / 10:10

Corporate News

STADA sales companies very successful in large-volume 7th AOK tender in the German generics market

Bad Vilbel, November 23, 2011 – In the view of the Executive Board, the STADA sales companies STADApharm GmbH, ALIUD PHARMA GmbH and cell pharm Gesellschaft für pharmazeutische und diagnostische Präparate mbH were very successful in the 7th round of AOK tenders of the Allgemeinen Ortskrankenkassen (AOK) for discount agreements pursuant to Section 130 a SGB V valid throughout Germany.

In the framework of this most recent AOK round with a total tender volume of approx.
EUR 1.2 billion, the three STADA sales companies concluded contracts for a total of 18 active ingredients – including some product launches and in-house production as well as a top-selling product Fentanyl – with the AOK, the largest German public health insurance organization, of which about 1/3 of patients covered by state insurance in Germany are members.

Nine of the active ingredients awarded are thereby accounted for by ALIUD PHARMA, five active ingredients by STADApharm, one active ingredient by cell pharm, two active ingredients by the bidder consortium ALIUD/STADApharm and one active ingredient by the bidder consortium ALIUD/Pfizer. The contracts are legally effective and take effect on
April 1, 2012. They have a regular term of two years. In general, the respective STADA sales company – or the respective bidder consortium – is the single contract partner (single source) of the AOK for the awards. Overall, the STADA sales companies did significantly better than competitors with these results in the 7th AOK tender round and thereby confirm the strong performance at AOK.

In view of these newly concluded large-volume discount agreements with the AOK and the recently received awards for discount agreements on a multiple-award basis (multi-source) with other public health insurance organizations, the STADA Executive Board expects the Group’s market share according to volume in the German market to increase further – as it already had in the third quarter of 2011.

Additional information:
STADA Arzneimittel AG / Corporate Communications / Stadastraße 2-18 / D – 61118 Bad Vilbel /
Phone: +49 (0) 6101 603-113 / Fax: +49 (0) 6101 603-506 / E-Mail: communications@stada.de
Or visit us in the Internet at www.stada.com .

End of Corporate News

23.11.2011 Dissemination of a Corporate News, transmitted by DGAP – a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

DGAP’s Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

Language:	English
Company:	STADA Arzneimittel AG
	Stadastraße 2-18
	61118 Bad Vilbel
	Germany
Phone:	+49 (0)6101 603- 113
Fax:	+49 (0)6101 603- 506
E-mail:	communications@stada.de
Internet:	www.stada.de
ISIN:	DE0007251803, DE0007251845,
WKN:	725180, 725184,
Listed:	Regulierter Markt in Düsseldorf, Frankfurt (Prime Standard); Freiverkehr in Berlin, Hamburg, Hannover, München, Stuttgart

End of News DGAP News-Service

147406  23.11.2011